10th International conference on sarcopenia, cachexia and muscle wasting

Friday, 8 December 2017

8:00-8:45 Special sessions: pre-registrations only

Statistical Seminar
Chairs: Jennifer Le-Rademacher, USA and  Jeffrey Crawford, USA

Ken Fearon Career Café – Meet the Mentors
Coordinated by Mitja Lainscak, Slovenia

Session A
9:00-10:50 OPENING SESSION 1

Stefan Anker, Germany,
Maurizio Muscaritoli, Italy, Filippo Rossi-Fanelli, Italy

Welcome by the Chairs

“Hippocrates” clinical science key note lecture
Luigi Ferrucci, USA

Frailty in 2017
Bruno Vellas, France

Sex differences in cachexia, sarcopenia and wasting disorders
James Carson, USA

Research gaps from the NCI consensus
Joanne Elena, USA

A payer perspective on cachexia and sarcopenia
Bette Caan, USA

10:50-11:20 Coffee Break

Session B
11:20-13:00 OPENING SESSION 2

Chairs: Josep Argiles, Spain and Andrea Bonetto, USA

“Prometheus” basic science key note lecture
William Evans, USA

News from proteomic and gene expression data related to aging and cachexia
H. Alexander Ebhardt, Ireland

Cause of death in sarcopenia & cachexia
Stefan Anker, Germany

Metabolic modulation by nutrients
Maurizio Muscaritoli, Italy

Precision medicine for cachexia
John Morley, USA

13:15-14:15 Lunch seminar(s)

14:30-16:00 – 2 parallel sessions

Session C
14:30-16:00 Clinical Track: Translating sarcopenia research across diseases  

Chair: Zudin Puthucheary, UK

Skeletal muscle ammonia metabolism in non-hepatological disease
Srinivasan Dasarathy, USA

What can cancer cachexia rehabilitation trials learn from critical care rehabilitation?
Linda Denehy, Australia

Separating inflammation and deconditioning as contributors to muscle wasting in COPD
Paul Greenhaff, UK

Molecular signaling homology across muscle wasting conditions

Sarcopenia in 2017 – what is new?
Francesco Landi, Italy

Session D
14:30-16:00 Basic track: Mechanisms of muscle wasting

Chairs: Denis Guttridge, USA and Paola Costelli, Italy

Autophagy dysregulation in muscle stem cells during aging

Mechanisms of pathological replacement of skeletal muscle tissue with adipose tissue
Renata Dmitrieva*, Russia

The role of lysosomes in body wasting
Jochen Springer, Germany

ER stress and UPR in skeletal muscle health and disease
Ashok Kumar, USA

Role of JAK/STAT signalling in muscle wasting
Teresa Zimmers, USA 

Mitochondrial impairment in skeletal muscle wasting
Antonio Zorzano, Spain

16:00-17:00 Coffee break & science

16:05-16:55 Poster Viewing Session 1 

16:10-16:50 Rapid Fire Abstract Session 1
Chairs: Andrea Bonetto, Italy and David Waning, USA

17:00-18:30 – 2 parallel sessions

Session E
17:00-18:30 Clinical track: Biological versus numerical aging

DNA methylation and the biological clock
Stephan Beck,* UK

Frailty scoring: biological aging phenotypes in the critically ill survivors
Zudin Puthucheary, UK

Relationship between aging and physiological function
Stephen Harridge*, UK

Nutritional status and satiety and the interaction with biological ageing
Alessandro Laviano, Italy

Panel discussion

Session F
17:00-18:30 Basic Track: Tumor-secreted factors, cytokines and
concepts of
cachexia development

Chairs: Didier Attaix, France and Giovanni Mantovani, Italy

Metabolic regulators of cachexia in cancer
Pankaj Singh, USA

New insights on cancer cachexia
Denis Guttridge, USA

The muscle gp130 receptor’s role for cancer-induced anabolic resistance: therapeutic implications for improving cancer survival
James Carson, USA

Mechanisms of muscle atrophy and hypertrophy
David Glass*, USA

MIC-1 / GDF-15
Samuel Breit, Australia

18:30-19:30 Welcome reception & poster viewing 

Saturday, 9 December 2017

7:45-8:45        Morning symposia

 7:45-8:45        Joint session of SCWD & ESPEN

 8:00-8:45 Special sessions: pre-registrations only

Statistical Seminar
Chairs: Jennifer Le-Rademacher, USA and  Jeffrey Crawford, USA

Ken Fearon Career Café – Meet the Mentors
Coordinated by Mitja Lainscak, Slovenia

9:00-10:30 – 3 parallel sessions

Session G
9:00-10:30   Recent developments and updates on CT imaging for body composition analysis
Chairs: Andrew Coats, UK and Joanne Elena, USA

Methodological standards of CT imaging and its use as endpoint in clinical trials
Vickie Baracos, Canada

Clinical practice of anti-cancer treatment dose adaption by muscle mass data
Florian Strasser, Switzerland

CT based muscle radiodensity as prognostic marker

CT based assessment of muscle mass in clinical trials: the reality check and industry view

CT imaging in phase 2/3 trials – what the regulators expect to see?

Panel discussion

Session H
9:00-10:30  How to assess muscle mass and function using non-imaging techniques

Chairs: Stephan von Haehling, Germany and William Evans, USA

The need for accurate assessment of body composition in infants and children
Daniel Marks*, USA

The D3-creatine dilution method: methodology & new data
Richard Clark*, USA

MrOs: Longitudinal observational trial in older men – body composition and outcomes
Peggy Cawthon, USA

SPRINT-T – update 2017

Panel discussion

Session I
9:00-10:30      Young investigators awards session – clinical & basic

Chairs: Luigi Ferrucci, USA and Alessandro Laviano, Italy

Giovanni Mantovani, Italy

Teresa Zimmers, USA
Samuel Breit, Australia

10:30-11:30    Coffee break & science
10:35-11:25    Poster Viewing Session 2
10:40-11:20    Rapid Fire Abstract Session 2

11:30-13:00 – 3 parallel sessions

Session J
11:30-13:00    Muscle loss in liver diseases

Epidemiology and clinical significance of sarcopenia in liver cirrhosis
Mathias Plauth, Germany

Significance of sarcopenia and sarcopenic obesity in fatty liver
Manuela Merli, Italy

Molecular mechanisms of sarcopenia in liver cirrhosis
Michela Giusto*, Italy

Role of HiF in muscle wasting

Treatment approaches for muscle wasting in liver cirrhosis
Srinivasan Dasarathy, USA

Session K
11:30-13:00    Cachexia: not just muscle

James Carson, USA and
Jochen Springer, Germany

The bone-muscle cross-talk
David Waning, USA

Adipogenic drive in cancer-induced muscle wasting
Paola Costelli, Italy

Energy metabolism, mitochondria and cachexia in COPD
Annemie Schols, The Netherlands

Metabolic regulation of fat in cancer cachexia
Stefan Herzig, Germany

Protecting fat to gain muscle – a possible new therapeutic concept

Session L
11:30-13:00    Nutritional approaches to combat sarcopenia & cachexia

Chair: Nicolaas Deutz*, USA

 Malnutrition and Cachexia in cancer patients at first medical oncology visit
Maurizio Muscaritoli, Italy

Micronutrients in sarcopenia and age-related physical decline
Jerome Feige, Switzerland

Interaction exercise and nutrition in sarcopenia
Roger Fielding*, USA

The efficacy of a novel oral nutrition supplement in tackling sarcopenia in the elderly
Pol Grootswagers, The Netherlands

Proteins to treat sarcopenia
Jürgen Bauer, Germany

Trial experience in wasting disorders using nutritional approaches
Jann Arends, Germany

13:15-14:15    Satellite symposium sponsored by Helsinn

14:30-16:00 – 3 parallel sessions

Session M
14:30-16:00    Models of cachexia

Chairs: Stefan Herzig, Germany and Jochen Springer, Germany

Human xenografts as a suitable model for studying cancer cachexia
Andrew Judge, USA

Modeling cachexia: the impact of anti-neoplastic therapy
Andrea Bonetto, USA

Experimental models for aging and sarcopenia
Angèle Chopard*, France

New experimental model of cancer cachexia & kidney disease
Daniel Marks*, USA

Animal models that resemble human cancer cachexia: update 2017
Lisa Freeman, USA

Session N
14:30-16:00    Cachexia at its worst

Chairs: Vickie Baracos, Canada and Stephan von Haehling, Germany

Diagnostic criteria for the classification of cancer-associated weight loss

Wasting of muscle involved in swallowing and mastication
Florian Strasser, Switzerland

Diagnosis and management of oropharyngeal dysphagia
Pere Clavé*, Spain

Treating shortness of breath in advanced cancer cachexia – the muscle hypothesis
Andrew Coats, UK

Palliative care and anabolic therapies
Aminah Jatoi, USA

Session O
14:30-16:00    Targeting skeletal muscle – from research to clinical development

Biopsies of skeletal muscle – a source of new understanding
Volker Adams, Germany

Muscle satellite cells

Diabetes and muscle
Leocadio Rodríguez Mañas, Spain

Gene therapy approaches to treat cancer cachexia
Paul Gregorevic, Australia

Cachexia & sarcopenia – how to develop and get approved drugs there
Giuseppe Rosano, UK

16:00-17:00    Coffee break & science
16:05-16:55    Poster Viewing Session 3
16:10-16:50    Rapid Fire Abstract Session 3

17:00-18:30 – 3 parallel sessions

Session P
17:00-18:30    Rehabilitation in advanced eldery cancer patients with cachexia

Paolo Bossi, Italy and Florian Strasser, Switzerland

Muscle of the elderly and physical activity: balancing over- and Under-treatment
Francesco Landi, Italy

Exercise training as an effective tool to improve cancer-induced muscle wasting
Fabio Penna, Italy

Current trials in cancer studying physical activity, endurance and strength training
Vivianne Hess*, Switzerland

Rehabilitative-geriatric interventions in elderly advanced cancer patients: who will respond?
Pierre Soubeyran*, France

Anabolic interventions in men and women: is there emerging evidence?
Hans Wildiers*, Belgium

Session Q
17:00-18:30    Potential treatments for muscle wasting and cachexia

Chair: Volker Adams, Germany

MEK inhibitors as potential tools to improve cancer-induced muscle wasting
Erin Talbert, USA

MAGIC-F1 modulations to improve myogenesis
Maurilio Sampaolesi, Italy

Irisin, vitamin D and muscle-bone interactions
Maria Grano*, Italy

Drugs modifying catabolic/anabolic balance: ACE inhibitors + beta-blockers
Mitja Lainscak, Slovenia

What else is new – update from the big pharma pipeline
David Glass*, Switzerland

Session R
17:00-18:30    Muscle wasting and cachexia in chronic illnesses – update 2017

Chairs: Annemie Schols, The Netherlands and Kamyar Kalantar-Zadeh, USA


Chronic heart failure
Stephan von Haehling, Germany

Chronic kidney disease failure
Robert Mak, USA

Wolfram Doehner, Germany

Jeffrey Crawford, USA

Sunday, 10 December 2017

7:45-8:45        Morning symposia
7:45-8:45        Session of the Journal of Cachexia, Sarcopenia and Muscle (JCSM)

9:00-10:15 – 2 parallel sessions

Session S
9:00-10:15      Imaging methods for assessing muscle mass

Chairs: Vickie Baracos, Canada and Steven Heymsfield*, USA

Body impedance
Maria-Christina Gonzalez, Brazil

Cross-sectional: CT or MRI

Quadriceps contractile volume by MRI
Thomas Maden-Wilkinson, UK

Ultra-sound methods

Panel discussion

Session T
9:00-10:15      Frailty & sarcopenia – update 2017

Chairs: Bruno Vellas*, France and John Morley, USA

The physical frailty phenotype
Jeremy Walston*, USA

Treatment trials for frailty

Validating SARC-F
Jean Woo, Hong Kong

The role of T2DM in the development of sarcopenia and frailty
Theodore Malmstrom, USA

Treating sarcopenia

10:15-11:15    Coffee break & science
10:20-11:10    Poster Viewing Session 4

11:15-12:45 – 2 parallel sessions

Session U
11:15-12:45    Clinical trials in progress

Chairs: Aminah Jatoi, USA and Andrew Coats, UK

Re-testing fish oil for cachexia

Eccentric exercise for rheumatoid arthritis patients with muscle wasting
Patrick Lacarin*, France

Peptamen for weight loss
Andrew Hendifar*, USA

Cannabis for cancer-associated weight loss
Moran Grinberg, Israel

Sildenafil for cholangiocarcinoma or pancreas cancer: rationale and study design
Melinda Sheffield Moore*, USA

Session V
11:15-12:45    Intensive care unit myopathy: molecular signals and clinical observations

Chair: William Evans, USA

Introduction and historical data: nutritional intervention strategies
Nicolaas Deutz*, USA

ICU associated muscle wasting: molecular signals & contractile function in animal models

Inflammation as a trigger for rapid loss of muscle: pre-clinical and clinical data
Paul Greenhaff, UK

Molecular signals in skeletal muscle from ICU patients: the role of GDF-15
Mark Griffiths, UK

Clinical experience: treating muscle wasting in the ICU
Jörg Schefold*, Switzerland

12:45-13:15    Coffee break

13:15-14:45 – 2 parallel sessions

 Session W
13:15-14:45    Late breaking clinical trials & trial updates

Chairs: Andrew Coats, UK and Stefan Anker, Germany

Session X
13:15-14:45    Anorexia of disease, fasting metabolism and clinical outcome

Chair: Filippo Rossi-Fanelli, Italy 

Targeting the adipose tissue in cancer cachexia
Josep Argiles, Spain

Lessors from fasting metabolism: is there any benefit of anorexia during disease?
Alessandro Laviano, Italy

Gut-brain axis: role of microbiota in anorexia of disease
Serguei Fetissov, France

Filling the caloric gap during disease: does it ameliorate clinical outcomes?
Elisabeth De Waele*, Belgium

Gastrointestinal hormones: a suitable target to treat anorexia of disease ?

Session Y
14:45-15:45    Highlights of the congress

Stefan Anker, Germany
Maurizio Muscaritoli, Italy
Annemie Schols, The Netherlands

Basic science & pathophysiology
Annemie Schols, The Netherlands

Body composition
Steven Heymsfield*, USA

Stephan von Haehling, Germany

Cachexia in chronic illness
Kamyar Kalantar-Zadeh*, USA

Nutrition treatment
Roger Fielding*, USA

Treatment of cachexia
Andrew Coats, UK

Awards Ceremony
Best Poster Award
Young Investigators Award
Trainee Poster Award

*pending confirmation